Zak sends us a message
Meet Zak: smart, joyful, and spirited, he wants people to see the person behind the disease. For him, a handicap should never be a reason to see someone as different. ‘I focus on life, not on the disease’.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.